Comparison of Levofloxacin based therapy and Hybrid therapy for the treatment of Helicobacter pylori infectio
Phase 2
- Conditions
- Health Condition 1: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation
- Registration Number
- CTRI/2022/11/047108
- Lead Sponsor
- JIPMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
adult patients of age 18-80 years with peptic ulcer disease will be included
Exclusion Criteria
1.Previous eradication therapy.
2.Patients who have used antibiotics within the previous 4 weeks.
3.Past history of developing allergy to any antibiotic used in the study.
4.Patients who have undergone gastrectomy.
5.Coexisting of severe concomitant illness.
6. Pregnancy or lactating women.
7.Patients diagnosed with any malignancies.
Patients with portal gastropathy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare efficacy of H. pylori eradication between levofloxacin-based therapy and hybrid therapy in patients with upper gastrointestinal disease needing eradicationTimepoint: 6 weeks <br/ ><br>The assessment of eradication which determines the efficacy will be at 6 weeks following the completion of therapy
- Secondary Outcome Measures
Name Time Method To compare the compliance and adverse effects of levofloxacin-based therapy and hybrid therapy.Timepoint: Compliance will be measured at the end of therapy (2weeks). <br/ ><br>Adverse effects will be measured during and 1 week after the therapy (1-3 weeks of commencement of therapy )